Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating
lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC)
patients.
Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and
intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses
of MK-3475 prior to lumpectomy.